Cargando…
Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer Patients
Background: High mobility group box 1 protein (HMGB1) is known for its significant elevation in a multitude of tumors and benign diseases. In this study, we investigated the relevance of soluble HMGB1 for the prediction and monitoring of therapy response as well as the estimation of prognosis in adv...
Autores principales: | Handke, Nikolaus A., Rupp, Alexander B. A., Trimpop, Nicolai, von Pawel, Joachim, Holdenrieder, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924191/ https://www.ncbi.nlm.nih.gov/pubmed/33672622 http://dx.doi.org/10.3390/diagnostics11020356 |
Ejemplares similares
-
The role of High Mobility Group Box 1 (HMGB1) in colorectal cancer
por: Süren, Dinç, et al.
Publicado: (2014) -
High mobility group box 1 (HMGB1) quantified by ELISA that dose not cross-react with HMGB2
por: Yakabe, K, et al.
Publicado: (2005) -
The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases
por: Chen, Qingjie, et al.
Publicado: (2016) -
Role of High Mobility Group Box 1 (HMGB1) in SCA17 Pathogenesis
por: Lee, Li-Ching, et al.
Publicado: (2014) -
Developmental expression of high-mobility group box 1 (HMGB1) in the mouse cochlea
por: Liu, Wenjing, et al.
Publicado: (2023)